News

Germany's Merck KGaA in $3.9 billion deal to buy US biotech firm SpringWorks
Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...
Devdiscourse38m
Merck's Strategic $3.9 Billion Move: A Boon for Rare Cancer Therapies
Germany's Merck KGaA will acquire US biotech firm SpringWorks Therapeutics for $3.9 billion. This strategic move aims to ...